Thirty-one biotechs raised $1.8 billion in follow-ons in 4Q, bringing the 2012 total to $6.3 billion. The 4Q12 money is more than twice the $698.3 million raised by 13 companies in 4Q11, and the full-year total is more than 50% higher than the $4.2 billion raised in 2011. Moreover, 13 follow-ons last year rasied $100 million or more. Four of them collected more than $200 million: Amylin Pharmaceuticals Inc., which was later acquired by Bristol-Myers Squibb Co. (NYSE:BMY), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) and Vivus Inc. (NASDAQ:VVUS).

4Q12 follow